ProQR Therapeutics
PRQR
25 hedge funds and large institutions have $80.8M invested in ProQR Therapeutics in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 8 closing their positions.
146% more capital invested
Capital invested by funds: $32.9M → $80.8M (+$47.9M)
1.13% more ownership
Funds ownership: 33.55% → 34.68% (+1.1%)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.34M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$1.37M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$1.12M |
| 4 |
Millennium Management
New York
|
+$985K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$417K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.02M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$952K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$831K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$529K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$300K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Franklin Resources
San Mateo,
California
| – | -$952K | -309,700 | Closed |
|
|
SM
27
Sabby Management
Miami Beach,
Florida
| – | -$529K | -172,160 | Closed |
|
28
Principal Financial Group
Des Moines,
Iowa
| – | -$224K | -72,796 | Closed |
|
29
JP Morgan Chase
New York
| – | -$103K | -33,425 | Closed |
|
|
OAM
30
Oxford Asset Management
Oxford,
United Kingdom
| – | -$62K | -20,199 | Closed |
|
31
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$49K | -15,905 | Closed |
|
32
UBS Group
Zurich,
Switzerland
| – | -$9K | -2,897 | Closed |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| – | -$5K | -1,590 | Closed |
|
PRQR Hedge Fund Activity: Q2 2018 in Review
25 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2018, worth a combined $80.8M — up 146% from $32.9M a quarter earlier.
Fund positioning in PRQR was balanced in Q2 2018: 8 funds opened new positions, 8 closed out, 4 added to existing stakes and 6 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $3.34M. The largest seller was Artal Group, cutting an estimated $2.02M.
- 25 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $80.8M of ProQR Therapeutics stock for Q2 2018, up 146% quarter-over-quarter.
- 8 funds opened new ProQR Therapeutics positions in Q2 2018 and 8 closed out, a net change of 0 holders.
- The largest ProQR Therapeutics buyer in Q2 2018 was Adage Capital Partners, an estimated $3.34M added.
- The largest ProQR Therapeutics seller in Q2 2018 was Artal Group, an estimated $2.02M sold.
Based on aggregated 13F filings for Q2 2018.